Insmed reported $56.75M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
DBV Technologies DBVT:US 4.06M 1.37M
Acelrx Pharmaceuticals ACRX:US $ 7.34M 1.38M
Alimera Sciences ALIM:US $ 10.09M 273K
Biomarin Pharmaceutical BMRN:US $ 194.62M 22.94M
Cytokinetics CYTK:US $ 33.07M 736K
Dynavax Technologies DVAX:US $ 31.46M 2.66M
Gilead Sciences GILD:US $ 1.08B 567M
Heron Therapeutics HRTX:US $ 32.96M 1.42M
Insmed INSM:US $ 56.75M 8.52M
Mirati Therapeutics MRTX:US $ 53.95M 10.42M
Novartis NVS:US 3.5B 486M
Ophthotech OPHT:US $ 12.11M 4.11M
Regeneron Pharmaceuticals REGN:US $ 450M 109.6M
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Seattle Genetics SGEN:US $ 174.22M 36.71M
Ultragenyx Pharmaceutical RARE:US $ 67.31M 7.88M
Vertex Pharmaceuticals VRTX:US $ 215.2M 39.96M